Session: 902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
Hematology Disease Topics & Pathways:
Research, Viral, epidemiology, Bacterial, Lymphomas, non-Hodgkin lymphoma, Clinical Research, Fungal, B Cell lymphoma, Other Pathogens, Diseases, SARS-CoV-2/COVID-19, Infectious Diseases, Lymphoid Malignancies, Adverse Events
Methods: We conducted a preliminary evaluation, of an ongoing pooled analysis encompassing single agent BsAbs used in B-cell NHL with no prior use of alternate BsAbs. Exclusion criteria included studies reporting the use of BsAbs as part of combination therapy and trispecific antibodies.
Results: A total of 546 B-cell NHL patients (number of trials, n=4) were treated with BsAbs in the studied period. Pooled median follow up was 11.7 . Relevant adverse events included all grade neutropenia in 26.9% (n=147/546), grade III/IV neutropenia in 20% (n=109/546), all grade infections in 40.1% (n=219/546), grade III/IV infections in 16.8% (n=92/546), all grade pneumonia in 7.2% (n=17/235), and coronavirus 2019 (COVID-19) in 1.3% (n=3/235). Incidence of grade III/IV and all grade infections of the BsAbs in each study are shown in figure 1. In addition, all grade cytokine release syndrome was seen in 56.4% (n=308/546) and death was reported in 33 patients of which 4 (0.7%) were reported to be secondary to infections.
Conclusion: Data from this ongoing analysis better describes the various infectious risks of patients with B-cell NHL receiving BsAbs. Providers should remain vigilant regarding these risks and intervene promptly in such situations. The finalized pooled analysis with a larger sample size may corroborate these findings.
Disclosures: Chavez: Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Genmab: Honoraria; Epizyme: Speakers Bureau; Cellectar: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astra Zeneca: Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Research Funding; Lilly: Honoraria; Merck: Research Funding; Morphosys: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees. Vargas Madueno: Janssen: Consultancy, Other: Advisory Board. Sandoval-Sus: Genmab: Other: Advisory Board; Janssen: Other: Advisory Board; Genentech: Other: Ad Board; BeiGene: Other: Ad Board; Abbvie: Other: Ad Board; Seagen: Other: Advisory Board, Speakers Bureau; ADC Therapeutics: Other: Advisory Board; Incyte: Other: Advisory Board; MassiveBio: Other: Advisory Board; TG Therapeutics: Other: Advisory Board.
See more of: Oral and Poster Abstracts